SCOPUS 정보 검색 플랫폼

Volumn , Issue , 2013, Pages 43-56

The drug discovery process: General principles and some case histories

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349015147 PISSN: None EISSN: None Source Type: Book
DOI: 10.1016/B978-0-7020-4299-7.00004-4 Document Type: Chapter

Times cited : (7)

References (12)

2
- 0036635291
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
- Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery 2002, 1:493-502.
- (2002) Nature Reviews Drug Discovery , vol.1 , pp. 493-502
- Capdeville, R.¹ Buchdunger, E.² Zimmermann, J.³

3
- 0036527429
- Protein kinases - the major drug targets of the twenty-first century?
- Cohen P Protein kinases - the major drug targets of the twenty-first century?. Nature Reviews Drug Discovery 2002, 1:309-316.
- (2002) Nature Reviews Drug Discovery , vol.1 , pp. 309-316
- Cohen, P.¹

4
- 0031595885
- Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development
- Cragg GM Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. Medical Research Review 1998, 18:315-331.
- (1998) Medical Research Review , vol.18 , pp. 315-331
- Cragg, G.M.¹

5
- 0034677966
- Drug discovery: a historical perspective
- Drews J Drug discovery: a historical perspective. Science 2000, 287:1960-1964.
- (2000) Science , vol.287 , pp. 1960-1964
- Drews, J.¹

6
- 0033987746
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelognous leukemia
- Druker BJ, Lydon NB Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelognous leukemia. Journal of Clinical Investigation 2000, 105:3-7.
- (2000) Journal of Clinical Investigation , vol.105 , pp. 3-7
- Druker, B.J.¹ Lydon, N.B.²

7
- 0029947186
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
- Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996, 2:561-566.
- (1996) Nature Medicine , vol.2 , pp. 561-566
- Druker, B.J.¹ Tamura, S.² Buchdunger, E.³

8
- 0035810147
- Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001, 344:1031-1037.
- (2001) New England Journal of Medicine , vol.344 , pp. 1031-1037
- Druker, B.J.¹ Talpaz, M.² Resta, D.J.³

9
- 0030886937
- Managing the drug discovery/development interface
- Kennedy T Managing the drug discovery/development interface. Drug Discovery Today 1997, 2:436-444.
- (1997) Drug Discovery Today , vol.2 , pp. 436-444
- Kennedy, T.¹

10
- 0001531576
- American Chemical Society, Washington DC
- Lednicer D Chronicles of drug discovery 1993, vol. 3, American Chemical Society, Washington DC.
- (1993) Chronicles of drug discovery , vol.3
- Lednicer, D.¹

11
- 0003460428
- Swedish Pharmaceutical Press, Stockholm
- Östholm I Drug discovery: a pharmacist's view 1995, Swedish Pharmaceutical Press, Stockholm.
- (1995) Drug discovery: a pharmacist's view
- Östholm, I.¹

12
- 0034665713
- Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
- Schindler T, Bornmann W, Pellicana P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289:1938-1942.
- (2000) Science , vol.289 , pp. 1938-1942
- Schindler, T.¹ Bornmann, W.² Pellicana, P.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.